Journal Article

Chemotherapy receipt in affected BRCA1/2 and PALB2 carriers with operable breast cancer: the impact of early detection and pre-diagnostic awareness on clinical outcomes and treatment

Meterissian, Sarkis, Apostolova, Carla, Alhassan, Basmah, Boileau, Jean Francois, Foulkes, William D., Ferroum, Amina, Basik, Mark, Malagon, Talia, Prakash, Ipshita, Wong, Stephanie M., Sadinsky, Michaela Bercovitch, Martel, Karyne, Wong, Nora, Fleiszer, David

2025

Overview

Purpose While enhanced breast screening of germline pathogenic variant (GPV) carriers results in earlier stage at diagnosis, the impact of tumour biology and GPV on chemotherapy receipt in early-stage disease remains understudied. Methods We retrospectively reviewed treatment administered following a first diagnosis of BRCA1/2 - and PALB2 -associated breast cancer between 2002 and 2022. Chemotherapy receipt was compared according to tumor size, biologic subtype, and GPV. Subgroup analyses were performed in women with T1N0 disease and in those with pre-diagnostic awareness of their GPV. Results Overall, 309 affected BRCA1/2 and PALB2 carriers with a median age of 43 years at breast cancer diagnosis (range, 19–80 years) were included; 160 (51.8%) BRCA1 , 130 (42.1%) BRCA2 , and 19 (6.1%) PALB2 carriers. Chemotherapy was administered in 70.9% of index breast cancer cases and was significantly associated with younger age, tumor size, histologic grade, nodal status, and biologic subtype (all p  < 0.05). Chemotherapy receipt was 80.6% in BRCA1 -associated breast cancers compared to 56.9% in BRCA2 and 84.2% in PALB2 associated breast cancers ( p  < 0.001). In subgroup analysis of early stage, T1N0 disease, chemotherapy was administered in 78.9% BRCA1 and 59.5% BRCA2/PALB2 patients ( p  = 0.04). Pre-diagnostic awareness of a GPV in BRCA1/2 or PALB2 was associated with smaller invasive tumors (%T1, 50% vs. 32.9%; p  = 0.002) and node-negative invasive disease (87.1% vs. 72.2%), as well as a reduced likelihood of chemotherapy (59.7% vs. 74.3%, p  = 0.02). Conclusion Chemotherapy receipt is high in BRCA1/2 and PALB2 -associated breast cancers including in early stage, node-negative disease. Pre-diagnostic awareness is associated with a lower likelihood of requiring chemotherapy for a breast cancer diagnosis.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Biomedical and Life Sciences / Biomedicine / Biopsy / BRCA1 protein / BRCA1/2 / BRCA2 protein / Breast cancer / Breast neoplasms / Cancer / Cancer Research / Cancer therapies / Chemotherapy / Diagnosis / Endocrine therapy / Hereditary breast cancer / Human Genetics / Invasiveness / Mastectomy / Medical diagnosis / Oncology / Patient outcomes / Research ethics / Surgery / Tumors